Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS hosts the biggest HIV/AIDS event in its history
2007-10-05

The Chief Directorate: Community Service at the University of the Free State (UFS), in partnership with the Free State Department of Education, will host the biggest HIV/AIDS focus event in the history of the university.

The event will take place on Wednesday, 10 October 2007 on the Main Campus in Bloemfontein and the theme will be: Management of HIV/AIDS in the Workplace.

According to the Chief Director of Community Service at the UFS, the Rev Kiepie Jaftha, this event forms part of a wider role of his directorate to raise the level of awareness about the impact of HIV/AIDS within the university and the higher education sector in South Africa. It will also enhance the executive management’s buy-in and ownership of this role and incorporate the flow of HIV/AIDS information and activities into the core business of the UFS.

The focus will be on getting the executive management, middle management, aspiring managers and those who are affected by the decisions of the management, on board in the university’s endeavour to manage and create HIV/AIDS awareness in the workplace.

Most importantly, community members will also form an essential part of this event as the UFS strives to get them also involved in HIV/AIDS education and awareness.

“We hope to release the valve of denialism and stir the excitement amongst people, to encourage them to get involved in creating awareness within their workplaces, institutions and society,” said the Rev Jaftha.


To that effect, the Director of the Africa Centre for HIV/AIDS Management at the University of Stellenbosch, Prof. Jan du Toit, will deliver a keynote address. There will also be a mini-musical production called Lucky, the Hero, directed by the well-known stage performer and director of Educational Theatre and creative arts for the Africa Centre for HIV/AIDS Management, Prof. Jimmie Earl Perry.

The 25 tables for the event have been sold at a cost of R1 500 each and the beneficiaries thereof will be a local non-governmental organization (NGO), namely the Lebone Land Care Centre. The UFS has a long-standing relationship with the Lebone Land Care Centre, where students are sent as part of the implementation of their community service learning modules to enhance their practical skills. Now the university intends to formalise this partnership.

“I admire the holistic manner of approach the Lebone Land Care Centre uses towards caring for people who are infected and affected by HIV/AIDS and the way they make people realise that they can still live a meaningful life and add dignity and value to society,” enthused Rev Jaftha.

The NGO will also receive an award from Spar, one of the biggest supermarket groups in South Africa.

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@mail.ufs.ac.za
04 October 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept